IDEXX Laboratories, Inc. $IDXX Stock Holdings Lifted by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC lifted its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 28.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 8,662 shares of the company’s stock after buying an additional 1,904 shares during the quarter. Motley Fool Asset Management LLC’s holdings in IDEXX Laboratories were worth $5,860,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in IDXX. Virtus Advisers LLC purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $26,000. Park Place Capital Corp purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth approximately $29,000. WealthCollab LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth approximately $30,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of IDEXX Laboratories in the third quarter worth approximately $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its position in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock worth $37,000 after acquiring an additional 20 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

IDEXX Laboratories Price Performance

NASDAQ IDXX opened at $578.89 on Wednesday. The company has a quick ratio of 0.82, a current ratio of 1.12 and a debt-to-equity ratio of 0.19. The stock has a market capitalization of $45.66 billion, a PE ratio of 42.63, a price-to-earnings-growth ratio of 3.07 and a beta of 1.55. The company has a 50 day moving average price of $563.22 and a two-hundred day moving average price of $630.28. IDEXX Laboratories, Inc. has a 12-month low of $506.91 and a 12-month high of $769.98.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Tuesday, May 5th. The company reported $3.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.41 by $0.06. The firm had revenue of $1.14 billion during the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a net margin of 24.63% and a return on equity of 70.87%. The company’s revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, equities analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the topic of several analyst reports. Wall Street Zen downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating on the stock in a research report on Tuesday, April 28th. Weiss Ratings downgraded shares of IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Citigroup started coverage on shares of IDEXX Laboratories in a research report on Wednesday, April 15th. They set a “neutral” rating and a $650.00 price objective on the stock. Finally, Stifel Nicolaus lowered their price objective on shares of IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating on the stock in a research report on Tuesday, March 31st. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.